Global Joint Pain Injection Market - 2022-2029

Global Joint Pain Injection Market - 2022-2029

Market Overview

The global joint pain injections market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

A joint injection (intra-articular injection) is a medical procedure used to treat inflammatory joint disorders such as rheumatoid arthritis, psoriatic arthritis, gout, tendinitis, bursitis, Carpal Tunnel Syndrome, and osteoarthritis. A hypodermic needle is inserted into the afflicted joint, delivering a dosage of anti-inflammatory medication, the most frequent of which are corticosteroids. Because of its high viscosity, hyaluronic acid is sometimes used to replace bursa fluids. The procedure can also be done to remove excess fluid from the joint.

Market Dynamics

The growing prevalence of obesity in the population is expected to increase the use of these injections. Factors such as an increase in sedentary behavior and an aging population in both developed and developing countries are expected to increase the use of intra-articular injections. Furthermore, rising osteoarthritis and musculoskeletal disorders are expected to drive market growth.

Increase in prevalance of arthritis in the market will drive the market growth

The extension of the joint pain injections market is predicted to be influenced by rising incidences of joint pain in developed and emerging nations and the rapid development of injections that allow doctors to analyze the fundamental causes of pain and aid in reducing pain swiftly. The facet joint injections contain a portion of an anesthetic drug, which numbs the muscles, ligaments, and articular capsules. Increased demand for non-surgical care has been identified as a key element promoting facet joint injections output during the predicted period. Furthermore, it is predicted to contribute to the total build-up of the facet joint injection during the evaluation time, improving the focus on effective pain relief.

Arthritis is the biggest cause of disability among adults in the United States, according to the Arthritis Foundation. Approximately 54 million people and 300,000 newborns and toddlers have arthritis or another rheumatic disease in the US. By 2040, more than 78 million people in the US would have been diagnosed with arthritis. In addition, osteoarthritis is the most common type of arthritis, affecting over 31 million people in the United States. The rising prevalence of arthritis is expected to raise demand for disease-modifying treatments, propelling the joint pain injections market during the forecast period.

Obesity is linked to various joint problems, particularly those affecting the knee, such as knee discomfort and osteoarthritis. Global obesity has tripled since 1975, according to a fact sheet provided by the World Health Organization (WHO). In 2016, 1.9 bn people were overweight, with over 650 million adults falling into this category. Furthermore, in 2017, approximately 41 million children under five were obese. According to the 2015-2016 National Health and Nutrition Examination Survey (NHANES), more than one out of every four children of Hispanic descent aged 2 to 19 had obesity, and nearly half of all adults had obesity.

Arthritis is the cause of joint discomfort in the general population and a major source of disability and reduced mobility. Treatment options now available are insufficient because they largely focus on symptom alleviation and pain management. There are no medications that can cure, reverse, or stop the progression of diseases like osteoarthritis. Furthermore, some people are unable to get relief from present treatments and continue to be in pain, indicating significant unmet requirements among patients with joint discomfort. This opens up the market for advanced therapeutic options for joint pain injections.This contributes to the growth of the global joint pain injections market.

Lack of awareness about the injections or treatment is likely to hamper the market growth

The general public is unaware of joint pain injections. Hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections are all used to treat joint discomfort. The use of these injections necessitates a thorough understanding and training. Doctors and healthcare professionals are primarily responsible for administering joint pain injections to patients. Professionals are given the necessary tools and training to accomplish this. The lack of government measures to promote joint pain injections is a barrier to the market's growth. As a result, lack of product awareness would pose a significant hurdle to the joint pain injections market's growth throughout the forecast period.

COVID-19 Impact Analysis

COVID-19's appearance greatly impacted the global demand for joint pain injections. As a result of the COVID-19 epidemic, leading players in the industry have reported a drop in revenue from joint pain injection sales. The fall in revenue for the joint pain injections sector has been ascribed to a decrease in patient visits, reallocation of healthcare resources for COVID-19 management, and disruption in the supply chain of key market competitors. In addition, non-covid-related activities and elective surgical procedures, such as operations to relieve joint discomfort, were postponed by healthcare facilities. For example, according to a study published in the Journal of Bone and Joint Surgery, 72.6 percent of institutions impeded orthopedic surgeons' daily duties during the first half of 2020. According to the report, around half of the orthopedic practitioners were switched from conventional orthopedic work to COVID-19 patient treatment. Furthermore, because of the lockdown limitations in major markets for joint pain injections, commercial activities such as production and shipping were disrupted.

Segment Analysis

The hyaluronic acid injections segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The hyaluronic acid injection is the market leader in the joint pain injections area. Because human joints are continually subjected to wear and tear, hyaluronic acid, like synovial fluid, has great lubricating and shock-absorbing qualities, minimizing joint stiffness and discomfort. Corticosteroid injections are an adjuvant drug in joint pain because of their anti-inflammatory qualities and capacity to provide short-term relief in joint sprains suffered by sports and industrial workers. Thus, the rising demand for hyaluronic acid injections throughout the projected period would expand the joint pain injections market.

Furthermore, According to a rapid response report published by Candian Agency for Drug and Technologies in Health, viscosupplementation with hyaluronic acid is superior to intra-articular placebo and other conventional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), in terms of improving knee pain and function with minimal adverse effects in adults with knee osteoarthritis.

Geographical Analysis

North America region holds the largest market share of global joint pain injections market

North America is likely to influence the market because of the high frequency of musculoskeletal problems that cause joint aches. Increased public knowledge of non-invasive orthopedic therapies, ongoing implant technology innovation, and sophisticated healthcare facilities.

According to the Center for Disease Control and Prevention, chronic pain caused by arthritis affects millions of people in the US each year according to the Center for Disease Control and Prevention. About one in every four persons has arthritis, and 15 million people say they have significant joint pain due to it. A high rate of advanced technology adoption is also one of the reasons driving the market's growth in this area. Furthermore, prominent market competitors are investing heavily in research, which will ultimately boost the market in North America. Furthermore, the presence of many key players in North America is a major factor driving market growth.

However, Asia-Pacific is assessed to grow the fastest during the forecast period, owing to increased healthcare spending and increased public knowledge of non-invasive orthopedic therapies, ongoing implant technology innovation, and sophisticated healthcare facilities which contribute to the growth of the Asia-Pacific joint pain injections market.

Competitive Landscape

The joint pain injections market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Anika Therapeutics Inc, Bioventus, Ferring Pharmaceuticals Inc, Sanofi SA, Pfizer Inc, Eli Lilly and Company, Flexion Therapeutics Inc, Teva Pharmaceuticals, Zimmer Biomet, Dr.Reddy Laboratories. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the joint pain injections market globally. For instance in July 2019, Teva Pharmaceutical Industries Ltd. declared the launch of 1% Sodium Hyaluronate in the US market following approval from the US FDA's Center for Devices and Radiological Health. This product is used to treat pain associated with knee osteoarthritis.

Key Developments

In Nov 2020, Durolane, GELSYN-3, and SUPARTZ FX were added to the CVS Caremark Formulary by Bioventus Inc. It is used to treat osteoarthritis pains, and its inclusion will allow patients to learn about drug coverage terms.

In Dec 2019, Flexion Therapeutics Inc announced the approval of a supplemental New Drug Application by the US Food and Drug Administration to update the product label of ZILRETTA and provide more specific information about the product.

In July 2019, Teva Pharmaceutical Industries Ltd. declared the launch of 1% Sodium Hyaluronate in the US market following approval from the US FDA's Center for Devices and Radiological Health. This product is used to treat pain associated with knee osteoarthritis.

Bioventus

Overview: Bioventus Inc is a company that specializes in medical technology. The company is involved in the development and commercialization of orthobiologic products to treat patients with a wide range of musculoskeletal conditions. Ultrasound Bone Healing, Joint Therapies, and Bioventus Surgical are some of the company's products.

Product Portfolio:

Durolane: Durolane is alike to the fluid that surrounds your body's joints. This fluid serves as a lubricant and a shock absorber for the joints. Durolane is used to treat osteoarthritic knee pain. Durolane is typically prescribed when other arthritis medications have failed to provide relief.

Why Purchase the Report?

Visualize the composition of the global joint pain injections market segmentation by product ,injection types, joint type, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global joint pain injections market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global joint pain injections market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global joint pain injections market report would provide an access to an approximately 40+ market data table, 45+ figures and 175 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Joint Pain Injections Market– By Product

Pre-filled injections

Vials

Global Joint Pain Injections Market- By Injection Type

Corticosteroid Injections

Hyaluronic Acid Injections

Platelete Rich Plasma Injections

Others

Global Joint Pain Injections Market– By Joint Type

Knee and Ankle

Hip

Shoulder and Elbow

Others

Global Joint Pain Injections Market– By End User

Hospitals Pharmacies

Online Pharmacies

Retail Pharmacies

Others

Global Joint Pain Injections Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America